• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 144 filed by Medpace Holdings Inc.

    4/24/25 2:13:57 PM ET
    $MEDP
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care
    Get the next $MEDP alert in real time by email
    Form 144 Filer Information UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    Form 144

    NOTICE OF PROPOSED SALE OF SECURITIES
    PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933

    FORM 144

    144: Filer Information

    Filer CIK
    0001181154
    Filer CCC
    XXXXXXXX
    Is this a LIVE or TEST Filing? Radio button checked LIVE Radio button not checked TEST

    Submission Contact Information

    Name
    Phone
    E-Mail Address

    144: Issuer Information

    Name of Issuer
    Medpace Holdings, Inc.
    SEC File Number
    001-37856
    Address of Issuer
    5375 MEDPACE WAY
    CINCINNATI
    OHIO
    45227
    Phone
    (513) 579-9911
    Name of Person for Whose Account the Securities are To Be Sold
    DAVENPORT FRED B JR
    See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

    Relationship to Issuer
    Director

    144: Securities Information

    Title of the Class of Securities To Be SoldName and Address of the BrokerNumber of Shares or Other Units To Be SoldAggregate Market ValueNumber of Shares or Other Units OutstandingApproximate Date of SaleName the Securities Exchange
    Common
    Fidelity Brokerage Services LLC
    900 Salem Street
    Smithfield � RI � 02917
    1712516716.012874160904/24/2025
    NASDAQ


    Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

    144: Securities To Be Sold

    Title of the ClassDate you AcquiredNature of Acquisition TransactionName of Person from Whom AcquiredIs this a Gift?Date Donor AcquiredAmount of Securities AcquiredDate of PaymentNature of Payment *
    Common04/24/2025Option Granted - 08/13/2018IssuerCheckbox not checked171204/24/2025Cash

    * If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.



    Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

    144: Securities Sold During The Past 3 Months

    Nothing to ReportCheckbox checked

    144: Remarks and Signature

    Remarks
    Date of Notice
    04/24/2025

    ATTENTION:

    The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.
    Signature
    /s/ Daniel Tucci, as a duly authorized representative of Fidelity Brokerage Services LLC, as attorney-in-fact for Fred Davenport Jr.

    ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

    Get the next $MEDP alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $MEDP

    DatePrice TargetRatingAnalyst
    7/29/2025$305.00Neutral → Sell
    UBS
    7/23/2025$366.00Hold → Sell
    TD Cowen
    6/24/2025$300.00Equal Weight
    Barclays
    4/22/2025Outperform → Mkt Perform
    William Blair
    4/14/2025$328.00Buy → Hold
    TD Cowen
    3/24/2025$330.00Market Perform
    Leerink Partners
    10/23/2024$413.00 → $349.00Outperform → Neutral
    Robert W. Baird
    10/14/2024Buy
    Redburn Atlantic
    More analyst ratings

    $MEDP
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    General Counsel & Corp. Secy. Ewald Stephen P sold $1,350,000 worth of shares (3,000 units at $450.00), decreasing direct ownership by 22% to 10,343 units (SEC Form 4)

    4 - Medpace Holdings, Inc. (0001668397) (Issuer)

    7/29/25 6:02:22 PM ET
    $MEDP
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    Exec. VP, Operations Burwig Susan E sold $3,376,050 worth of shares (7,500 units at $450.14), decreasing direct ownership by 12% to 57,500 units (SEC Form 4)

    4 - Medpace Holdings, Inc. (0001668397) (Issuer)

    7/29/25 5:43:48 PM ET
    $MEDP
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    CEO Troendle August J. sold $21,901,093 worth of shares (48,487 units at $451.69), decreasing direct ownership by 5% to 962,615 units (SEC Form 4)

    4 - Medpace Holdings, Inc. (0001668397) (Issuer)

    7/29/25 5:37:42 PM ET
    $MEDP
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    $MEDP
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    General Counsel & Corp. Secy. Ewald Stephen P bought $652 worth of shares (2 units at $326.11), increasing direct ownership by 0.01% to 13,343 units (SEC Form 4)

    4 - Medpace Holdings, Inc. (0001668397) (Issuer)

    2/28/25 4:39:05 PM ET
    $MEDP
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    $MEDP
    SEC Filings

    View All

    SEC Form 144 filed by Medpace Holdings Inc.

    144 - Medpace Holdings, Inc. (0001668397) (Subject)

    8/19/25 3:00:59 PM ET
    $MEDP
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    SEC Form 144 filed by Medpace Holdings Inc.

    144 - Medpace Holdings, Inc. (0001668397) (Subject)

    7/28/25 4:35:13 PM ET
    $MEDP
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    SEC Form 10-Q filed by Medpace Holdings Inc.

    10-Q - Medpace Holdings, Inc. (0001668397) (Filer)

    7/22/25 4:07:17 PM ET
    $MEDP
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    $MEDP
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Medpace Holdings, Inc. Reports Second Quarter 2025 Results

    Revenue of $603.3 million in the second quarter of 2025 increased 14.2% from revenue of $528.1 million for the comparable prior-year period, representing a backlog conversion rate of 21.2%. Net new business awards were $620.5 million in the second quarter of 2025, representing an increase of 12.6% from net new business awards of $551.0 million for the comparable prior-year period, which resulted in a net book-to-bill ratio of 1.03x. Second quarter of 2025 GAAP net income was $90.3 million, or $3.10 per diluted share, versus GAAP net income of $88.4 million, or $2.75 per diluted share, for the comparable prior-year period. Net income margin was 15.0% and 16.7% for the second quarter o

    7/21/25 4:15:00 PM ET
    $MEDP
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    Medpace Holdings, Inc. to Report Second Quarter 2025 Financial Results on July 21, 2025

    Medpace Holdings, Inc. (NASDAQ:MEDP) ("Medpace") today announced that it will report its second quarter 2025 financial results after the market close on Monday, July 21, 2025. The Company will host a conference call the following morning, Tuesday, July 22, 2025, at 9:00 a.m. ET to discuss these results. To participate in the conference call, interested parties must register in advance by clicking on this link. While it is not required, it is recommended you join 10 minutes prior to the event start. Upon registration, all telephone participants will receive a confirmation email detailing how to join the conference call, including the dial-in number along with a unique PIN that can be used

    6/23/25 4:05:00 PM ET
    $MEDP
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    Medpace Holdings, Inc. Reports First Quarter 2025 Results

    Revenue of $558.6 million in the first quarter of 2025 increased 9.3% from revenue of $511.0 million for the comparable prior-year period, representing a backlog conversion rate of 19.2%. Net new business awards were $500.0 million in the first quarter of 2025, representing a decrease of 18.8% from net new business awards of $615.6 million for the comparable prior-year period, which resulted in a net book-to-bill ratio of 0.90x. First quarter of 2025 GAAP net income was $114.6 million, or $3.67 per diluted share, versus GAAP net income of $102.6 million, or $3.20 per diluted share, for the comparable prior-year period. Net income margin was 20.5% and 20.1% for the first quarter of 2025

    4/21/25 4:15:00 PM ET
    $MEDP
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    $MEDP
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Medpace downgraded by UBS with a new price target

    UBS downgraded Medpace from Neutral to Sell and set a new price target of $305.00

    7/29/25 7:37:12 AM ET
    $MEDP
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    Medpace downgraded by TD Cowen with a new price target

    TD Cowen downgraded Medpace from Hold to Sell and set a new price target of $366.00

    7/23/25 7:56:11 AM ET
    $MEDP
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    Barclays initiated coverage on Medpace with a new price target

    Barclays initiated coverage of Medpace with a rating of Equal Weight and set a new price target of $300.00

    6/24/25 8:08:46 AM ET
    $MEDP
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    $MEDP
    Leadership Updates

    Live Leadership Updates

    View All

    Medpace Holdings, Inc. Announces Senior Leadership Changes

    Appointment of Jesse Geiger as President and Kevin Brady as Chief Financial Officer Medpace Holdings, Inc. (NASDAQ:MEDP) ("Medpace") today announced the appointment of Jesse Geiger as president and Kevin Brady as chief financial officer, effective August 1, 2021. August Troendle will continue to serve as Medpace's chairman and chief executive officer. Geiger joined Medpace in 2007 as corporate controller and became chief financial officer in 2011. In 2014, Geiger expanded his role to include chief operating officer of laboratory operations. Geiger will continue to report to August Troendle. The newly created position of president will allow Troendle to continue to focus on the overall lon

    7/26/21 4:15:00 PM ET
    $MEDP
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    $MEDP
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13D/A filed by Medpace Holdings Inc. (Amendment)

    SC 13D/A - Medpace Holdings, Inc. (0001668397) (Subject)

    3/8/24 4:28:58 PM ET
    $MEDP
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    SEC Form SC 13D/A filed by Medpace Holdings Inc. (Amendment)

    SC 13D/A - Medpace Holdings, Inc. (0001668397) (Subject)

    2/28/24 5:04:01 PM ET
    $MEDP
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    SEC Form SC 13G/A filed by Medpace Holdings Inc. (Amendment)

    SC 13G/A - Medpace Holdings, Inc. (0001668397) (Subject)

    2/13/24 5:09:38 PM ET
    $MEDP
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    $MEDP
    Financials

    Live finance-specific insights

    View All

    Medpace Holdings, Inc. Reports Second Quarter 2025 Results

    Revenue of $603.3 million in the second quarter of 2025 increased 14.2% from revenue of $528.1 million for the comparable prior-year period, representing a backlog conversion rate of 21.2%. Net new business awards were $620.5 million in the second quarter of 2025, representing an increase of 12.6% from net new business awards of $551.0 million for the comparable prior-year period, which resulted in a net book-to-bill ratio of 1.03x. Second quarter of 2025 GAAP net income was $90.3 million, or $3.10 per diluted share, versus GAAP net income of $88.4 million, or $2.75 per diluted share, for the comparable prior-year period. Net income margin was 15.0% and 16.7% for the second quarter o

    7/21/25 4:15:00 PM ET
    $MEDP
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    Medpace Holdings, Inc. to Report Second Quarter 2025 Financial Results on July 21, 2025

    Medpace Holdings, Inc. (NASDAQ:MEDP) ("Medpace") today announced that it will report its second quarter 2025 financial results after the market close on Monday, July 21, 2025. The Company will host a conference call the following morning, Tuesday, July 22, 2025, at 9:00 a.m. ET to discuss these results. To participate in the conference call, interested parties must register in advance by clicking on this link. While it is not required, it is recommended you join 10 minutes prior to the event start. Upon registration, all telephone participants will receive a confirmation email detailing how to join the conference call, including the dial-in number along with a unique PIN that can be used

    6/23/25 4:05:00 PM ET
    $MEDP
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    Medpace Holdings, Inc. Reports First Quarter 2025 Results

    Revenue of $558.6 million in the first quarter of 2025 increased 9.3% from revenue of $511.0 million for the comparable prior-year period, representing a backlog conversion rate of 19.2%. Net new business awards were $500.0 million in the first quarter of 2025, representing a decrease of 18.8% from net new business awards of $615.6 million for the comparable prior-year period, which resulted in a net book-to-bill ratio of 0.90x. First quarter of 2025 GAAP net income was $114.6 million, or $3.67 per diluted share, versus GAAP net income of $102.6 million, or $3.20 per diluted share, for the comparable prior-year period. Net income margin was 20.5% and 20.1% for the first quarter of 2025

    4/21/25 4:15:00 PM ET
    $MEDP
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care